Skip to main content
. 2014 Jul 15;83(3):235–239. doi: 10.1212/WNL.0000000000000593

Figure 2. Survival of patients with CR vs others.

Figure 2

Overall (A) and progression-free (B) survival of patients treated with HD-MTX or HD-MTX/R (both groups combined) who did achieve a CR vs those who did not. CR = complete response; HD-MTX = high-dose methotrexate; R = rituximab.